Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial중국 성인에서 SARS-CoV-2 BNT162b1 mRNA 백신 접종 후 면역 지속성 및 안전성: 무작위, 위약 대조, 이중 맹검 1상 시험Clinical Trial Published on 2022-08-012022-09-12 Journal: Advances in therapy [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Administered Antibody titer BNT162b1 candidate vaccine Chinese COVID declined dose geometric mean titer GMT GMTs immune persistence maintain mRNA mRNA vaccine NAb neutralizing antibody nucleoside-modified mRNA Older participant Participants persistence Phase 1 Registered reported Safety safety profile SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event the vaccine vaccination vaccination schedule Vaccine was determined [DOI] 10.1007/s12325-022-02206-1 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study일본 참가자의 S-268019-b 또는 BNT162b2 추가 용량의 면역원성과 안전성: 2/3상, 무작위, 관찰자 맹검, 비열등성 연구의 중간 보고서Clinical Trial Published on 2022-07-302022-09-11 Journal: Vaccine [Category] MERS, 변종, 임상, 진단, [키워드] 95% CI analyzed Anti-spike antibodies BNT162b2 booster booster dose Booster vaccine clinical clinical trial co-primary endpoint co-primary endpoints COVID-19 Delta elicited fatigue Fever geometric mean geometric mean titer GMT GMT ratio immunization immunogenicity Immunoglobulin Immunoglobulin G injection Injection-site pain Interim report Interim result interim results Japanese Live virus MOST myalgia neutralization test Neutralizing antibodies neutralizing antibody observer observer-blinded omicron P-value participant phase 2/3 produced pseudovirus Randomized reactogenicity recombinant Recombinant spike protein regimen reported robust Safe SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Spike protein subgroups T-cell Response Vaccine variant [DOI] 10.1016/j.vaccine.2022.06.032 PMC 바로가기 [Article Type] Clinical Trial
Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection병원 내 SARS-CoV-2 델타 변이형 돌발성 감염에 대한 백신 접종 후 항체 평가Observational Study Published on 2022-07-252022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-S IgG Anti-spike anti-spike antibody antibody Asymptomatic B.1.617.2 BNT162b2 booster vaccination Breakthrough infection Care Casirivimab characterized collected coronavirus Course Delta variants diagnosed Diagnosis eight estimation geometric mean geometric mean titer GMT hospital Humoral immunity IgG Imdevimab Infection Inpatient LAMP Loop-mediated isothermal amplification lowest measurement Mild mild to moderate mild to moderate severity moderate monoclonal antibody mRNA vaccination nosocomial observational study outbreak public health quantified RBD protein remained respiratory retrospective risk RT-PCR SARS-CoV-2 SARS-CoV-2 delta SARS-COV-2 infection SARS-CoV-2 vaccination Sequencing serological serum sample serum samples Seven severe acute respiratory syndrome Coronavirus severity therapy Treatment uninfected vaccination variant virus viruses was done whole-genome sequencing [DOI] 10.1371/journal.pone.0272056 PMC 바로가기 [Article Type] Observational Study
Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study한국 성인에서 Ad26.COV2.S의 면역원성과 반응성: 전향적 코호트 연구Article Published on 2022-07-112022-09-11 Journal: Journal of Korean medical science [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Adenovirus Adenovirus Vector Adverse adverse event adverse events AEs anti-S IgG Anti-spike baseline cellular immunity conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 decrease Delta Dilution enrolled enzyme enzyme-linked immunospot assay evaluated fatigue Fever followed by geometric mean geometric mean titers GMT GMTs GRADE Humoral immunity IgG antibody immunogenic immunogenicity injection site pain interferon interferon-γ Korean mononuclear cell MOST myalgia NAb titer Neutralizing Neutralizing activity neutralizing antibody responses omicron Omicron variant Omicron variants outcome pandemic participant Peripheral blood Prospective prospective cohort study resolved respiratory Safe SARS-CoV-2 serious AEs severe acute respiratory syndrome Coronavirus Single-dose South Korea T-cell immunity T-cell Response T-cell responses the median U/mL university hospital vaccination Vaccines variant variants Viral Viral variants waning immunity wild-type WT SARS-CoV-2 [DOI] 10.3346/jkms.2022.37.e210 PMC 바로가기 [Article Type] Article
Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization회복기 혈장 기증자는 예방 접종 후 SARS-CoV-2의 항원 변이체에 대한 향상된 교차 반응성 중화 항체 반응을 보여줍니다Article Published on 2022-07-012022-09-11 Journal: Transfusion [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Alpha anti-SARS-CoV-2 anti-spike antibody antibody Antibody neutralization antigenic antigenic variant antigenic variants antigenic variation automated Beta circulating convalescent convalescent plasma COVID-19 cross-reactive Delta determined by Donor dose Effect Elecsy focus geometric mean geometric mean titer GMT GMTs immunization infected with SARS-CoV-2 Live virus microneutralization NAb NAb titers NAbs neutralization neutralization potency neutralization test neutralize Neutralizing antibodies neutralizing antibody Neutralizing antibody response omicron Pfizer plasma Predictive prototype Quantitative reactivity reduction ROC analysis Roche Sample SARS-CoV-2 SARS-CoV-2 strain specificity strain Strains Therapeutic benefit therapy titers treat vaccination Vaccinations vaccine dose Zeneca [DOI] 10.1111/trf.16934 PMC 바로가기 [Article Type] Article
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipientsBNT162b2 및 CoronaVac 수용자의 중화 항체 반응에 대한 중등도 내지 중증 간 지방증의 효과Article Published on 2022-07-012022-09-12 Journal: Clinical and molecular hepatology [Category] MERS, 진단, [키워드] BNT162b2 control group control subjects CoronaVac COVID-19 COVID-19 vaccine dose Effect Fatty liver FIVE geometric mean titer GMT groups hepatic steatosis Live virus Liver cirrhosis neutralising antibody no difference no statistical difference Non-alcoholic fatty liver disease of BNT162b2 outcome parameter Patient proportion recipient SARS-CoV-2 secondary seroconversion rate subject vaccination Vaccine while [DOI] 10.3350/cmh.2022.0082 PMC 바로가기 [Article Type] Article
Inactivated SARS-CoV-2 vaccine in primary Sjögren’s syndrome: humoral response, safety, and effects on disease activity원발성 쇼그렌 증후군에서 비활성화된 SARS-CoV-2 백신: 체액 반응, 안전성 및 질병 활동에 대한 영향Clinical Trial Published on 2022-07-012022-09-12 Journal: Clinical Rheumatology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI activity Adverse age anti-SARS-CoV-2 autoantibody Autoimmune disease booster dose comparable Control controls COVID-19 Deleterious detrimental Disease activity dose Effect event female Frequency geometric mean titer GMT humoral IgG immunogenicity index IQR Mild moderate Neutralizing activity neutralizing antibody participant Patient patients Point S1/S2 Safe Safety SARS-CoV-2 SARS-CoV-2 vaccine Seroconversion Sex Sjögren’s syndrome syndrome Trial Vaccine were assessed [DOI] 10.1007/s10067-022-06134-x PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial무작위 2상 시험에서 BBIBP-CorV 수용자에서 하이브리드형 백신 부스터의 안전성 및 면역원성Clinical Trial Published on 2022-06-272022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] 1:1 Administered Adverse reaction Adverse reactions age Antigen antigens BBIBP-CorV boost booster booster dose conducted dose double-blind elicited evaluate GMT greater group healthy Heterologous homologous IgG antibodies IgG antibody immunogenic immunogenicity incidence Neutralizing and IgG antibodies neutralizing antibody omicron Omicron variant participant Phase 2 phase 2 trial Randomized receive recipient recombinant COVID-19 vaccine regimens Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 strain significantly higher three groups United Arab Emirate United Arab Emirates Vaccine variant variants of concern VOCs [DOI] 10.1038/s41467-022-31379-0 PMC 바로가기 [Article Type] Clinical Trial
Antibody Responses to SARS-CoV-2 in Children With COVID-19COVID-19에 걸린 어린이의 SARS-CoV-2에 대한 항체 반응Article Published on 2022-06-222022-09-11 Journal: Journal of the Pediatric Infectious Diseases Socie [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age analyzed anti-S IgG anti-SARS-CoV-2 IgG Anti-spike antibody antibody level antibody levels Antibody Response Asymptomatic blood sample Blood samples caused children children with COVID-19 conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic Cutoff detectable effective evaluate feature geometric mean geometric mean titer geometric mean titers GMT GMTs highest humoral immune response humoral immune responses IgG immune responses immune system Infection longitudinal study neutralizing antibody peaked positive positive rate positive rates reached remained respiratory response SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus South Korea symptom onset symptomatic Vaccine development were measured with COVID-19 [DOI] 10.1093/jpids/piac012 PMC 바로가기 [Article Type] Article
Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infectionArticle Published on 2022-06-072022-10-04 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome benefit boost cellular clinical trial convalescent coronavirus coronavirus disease COVID-19 COVID-19 vaccine dose doses driving effective vaccine Efficacy evaluated geometric mean titer GMT greater Heterologous highlighting homologous human sera humoral immune response immune response immunize low dose lower airways mice mRNA mRNA vaccine NAb neutralizing antibody non-human primate non-human primates offer pandemic populations prefusion prime-boost regimen Protective protective immunity provided reduction regimen regimens replicate rhesus macaque rhesus macaques RNA vaccines Safe SAM SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine spike glycoprotein Spread T cell response tested Translational immunology vaccination Vaccine viral replication [DOI] 10.1038/s41467-022-31005-z PMC 바로가기 [Article Type] Article